<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Identification of key molecules that drive <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> is critical for the development of new modalities for the prevention of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> progression </plain></SENT>
<SENT sid="1" pm="."><plain>Using multiple models of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, we show that activity of the extracellular matrix-modifying enzyme <z:chebi fb="0" ids="32568">lysyl</z:chebi> oxidase (LOX) is essential for stimulating endothelial cells in vitro and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>We show that LOX activates Akt through platelet-derived growth factor receptor β (PDGFRβ) stimulation, resulting in increased VEGF expression </plain></SENT>
<SENT sid="3" pm="."><plain>LOX-driven <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> can be abrogated through targeting LOX directly or using inhibitors of PDGFRβ, Akt, and VEGF signaling </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, we show that LOX is clinically correlated with VEGF expression and blood vessel formation in 515 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patient samples </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, we validate our findings in a <z:hpo ids='HP_0003002'>breast cancer</z:hpo> model, showing the universality of these observations </plain></SENT>
<SENT sid="6" pm="."><plain>Taken together, our findings have broad clinical and therapeutic implications for a wide variety of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> types </plain></SENT>
</text></document>